These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 29345540)
1. Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Itoga NK; Minami HR; Chelvakumar M; Pearson K; Mell MM; Bendavid E; Owens DK Vasc Med; 2018 Apr; 23(2):97-106. PubMed ID: 29345540 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management. Minami HR; Itoga NK; George EL; Garcia-Toca M J Vasc Surg; 2021 Dec; 74(6):2030-2039.e2. PubMed ID: 34175383 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. Xing Y; Qiu Y; Yang L; Yuan Z; Wang Y Int J Cardiol; 2023 Jan; 371():420-426. PubMed ID: 36228765 [TBL] [Abstract][Full Text] [Related]
4. Screen or not to screen for peripheral arterial disease: guidance from a decision model. Vaidya A; Joore MA; Ten Cate-Hoek AJ; Ten Cate H; Severens JL BMC Public Health; 2014 Jan; 14():89. PubMed ID: 24476213 [TBL] [Abstract][Full Text] [Related]
5. Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population. van Kempen BJ; Ferket BS; Steyerberg EW; Max W; Myriam Hunink MG; Fleischmann KE Int J Cardiol; 2016 Jan; 203():422-31. PubMed ID: 26547049 [TBL] [Abstract][Full Text] [Related]
6. Ankle brachial index screening in asymptomatic older adults. Taylor-Piliae RE; Fair JM; Varady AN; Hlatky MA; Norton LC; Iribarren C; Go AS; Fortmann SP Am Heart J; 2011 May; 161(5):979-85. PubMed ID: 21570532 [TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113 [TBL] [Abstract][Full Text] [Related]
8. Clinical Benefit, Harm, and Cost Effectiveness of Screening Men for Peripheral Artery Disease: A Markov Model Based on the VIVA Trial. Lindholt JS; Søgaard R Eur J Vasc Endovasc Surg; 2021 Jun; 61(6):971-979. PubMed ID: 33846075 [TBL] [Abstract][Full Text] [Related]
9. Screening of peripheral arterial disease in primary health care. Tóth-Vajna Z; Tóth-Vajna G; Gombos Z; Szilágyi B; Járai Z; Berczeli M; Sótonyi P Vasc Health Risk Manag; 2019; 15():355-363. PubMed ID: 31686829 [TBL] [Abstract][Full Text] [Related]
10. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Blake GJ; Ridker PM; Kuntz KM Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581 [TBL] [Abstract][Full Text] [Related]
11. Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Guirguis-Blake JM; Evans CV; Redmond N; Lin JS JAMA; 2018 Jul; 320(2):184-196. PubMed ID: 29998343 [TBL] [Abstract][Full Text] [Related]
12. Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement. ; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Tseng CW; Wong JB JAMA; 2018 Jul; 320(2):177-183. PubMed ID: 29998344 [TBL] [Abstract][Full Text] [Related]
13. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? Sigvant B; Henriksson M; Lundin F; Wahlberg E Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673 [TBL] [Abstract][Full Text] [Related]
14. High prevalence of peripheral arterial disease in hypertensive patients: the Evaluation of Ankle-Brachial Index in Hungarian Hypertensives screening program. Farkas K; Járai Z; Kolossváry E; Ludányi A; Clement DL; Kiss I; J Hypertens; 2012 Aug; 30(8):1526-32. PubMed ID: 22743684 [TBL] [Abstract][Full Text] [Related]
16. Peripheral arterial disease and ankle-brachial index abnormalites in young and middle-aged HIV-positive patients in lower Silesia, Poland. Kwiatkowska W; Knysz B; Arczyńska K; Drelichowska J; Czarnecki M; Gąsiorowski J; Karczewski M; Witkiewicz W PLoS One; 2014; 9(12):e113857. PubMed ID: 25503743 [TBL] [Abstract][Full Text] [Related]
17. To screen or not to screen for peripheral arterial disease in subjects aged 80 and over in primary health care: a cross-sectional analysis from the BELFRAIL study. Bergiers S; Vaes B; Degryse J BMC Fam Pract; 2011 May; 12():39. PubMed ID: 21605447 [TBL] [Abstract][Full Text] [Related]
18. Impact of Ankle Brachial Index Calculations on Peripheral Arterial Disease Prevalence and as a Predictor of Cardiovascular Risk. Pereira Filho AJG; Sartipy F; Lundin F; Wahlberg E; Sigvant B Eur J Vasc Endovasc Surg; 2022; 64(2-3):217-224. PubMed ID: 35537637 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease. Lee JY; Lee SW; Lee WS; Han S; Park YK; Kwon CH; Jang JY; Cho YR; Park GM; Ahn JM; Kim WJ; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ JACC Cardiovasc Interv; 2013 Dec; 6(12):1303-13. PubMed ID: 24355120 [TBL] [Abstract][Full Text] [Related]
20. Effects of Three Different Methods Defining Onset of Peripheral Artery Disease on the Assessments of Incidence and Important Predictors - Results from the German Epidemiological Trial on Ankle Brachial Index (getABI). Lupilov A; Krause D; Klaassen-Mielke R; Trampisch HJ; Rudolf H Vasc Health Risk Manag; 2021; 17():421-429. PubMed ID: 34335027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]